Skip to main content

New Leukemia Drug Approved: Gives Hope To Cancer Patients

By Jim Greene

The United States Food and Drug Administration has approved a new leukemia treatment today. It was produced by Teva Pharmaceutical Industries Ltd under the brand name Synribo. The drug is known as omacetaxine mepesuccinate and it treats a very specific form of leukemia. The type of cancer is called chronic myelogenous, which affects the blood and bone marrow. It is known by its acronym CML. It is a common form of leukemia and has a survival rate of 89%.

The treatment of CML is through multiple drugs known as tyrosine kinase inhibitors. This new drug is an option for patients who are unable to take the regular treatment, or do not respond to it. Richard Pazdur, director of the Office of Hematology and Oncology Products from the FDA’s Center for Drug Evaluation and Research issued a statement about the new drug. “Today’s approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML.”

Hopefully with the new drug available, the survival rate for CML will be elevated.

Source: Reuters

Jim Greene

Contributor

Jim has spent the last 5 years writing for a variety of health-related websites. At Activebeat, James is an essential member of the editorial team, providing information on exercise, diet & nutrition and men’s health – among many other things.

Trending Health News

Explore

5 Cheap Anti-Aging Hacks That Will Keep You Looking Younger For Less
By Chris Brown Your Health

5 Cheap Anti-Aging Hacks That Will Keep You Looking Younger For Less

We all want to keep that youthful glow. We’re willing to try all sorts of things at the mere promise of looking young for longer. There certainly are a lot of products to choose from, and even more advice to work through. In reality, winning the battle against aging isn’t as complicated as a lot […]

Read More about 5 Cheap Anti-Aging Hacks That Will Keep You Looking Younger For Less

4 min read